Christian Rausch

Christian Rausch

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
CRChristian Rausch
Christian Rausch
MRMaja Rothenberg-Thurley
Maja Rothenberg-Thurley
ADAnnika Dufour
Annika Dufour
SSStephanie Schneider
Stephanie Schneider
HGHanna Gittinger
Hanna Gittinger
KMKlaus Metzeler H Metzeler
Klaus Metzeler H Metzeler
The revised 2022 European LeukemiaNet (ELN) AML risk stratification system requires validation in large, homogeneously treated cohorts. We studied 1118 newly diagnosed AML patients (median age, 58 years; range, 18–86 years) who received cytarabine-based induction chemotherapy between 1999 and 2012 and compared ELN-2022 to the previous ELN-2017 risk classification. Key findings were validated in a cohort of 1160 mostly younger patients. ELN-2022 reclassified 15% of patients, 3% into more favorable, and 12% into more adverse risk groups. This was mainly driven by patients reclassified from intermediate- to adverse-risk based on additional myelodysplasia-related mutations being included as adverse-risk markers. These patients (n = 79) had significantly better outcomes than patients with other adverse-risk genotypes (5-year OS, 26% vs. 12%) and resembled the remaining intermediate-risk group. Overall, time-dependent ROC curves and Harrel’s C-index controlling for age, sex, and AML type (de novo vs. sAML/tAML) show slightly worse prognostic discrimination of ELN-2022 compared to ELN-2017 for OS. Further refinement of ELN-2022 without including additional genetic markers is possible, in particular by recognizing TP53-mutated patients with complex karyotypes as “very adverse”. In summary, the ELN-2022 risk classification identifies a larger group of adverse-risk patients at the cost of slightly reduced prognostic accuracy compared to ELN-2017.

7 September 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
JEJan-Niklas Eckardt
Jan-Niklas Eckardt
MBMarius Bill
Marius Bill
CRChristian Rausch
Christian Rausch
KMKlaus Metzeler H Metzeler
Klaus Metzeler H Metzeler
KSKarsten Spiekermann
Karsten Spiekermann
CRChristoph Röllig
Christoph Röllig

1 August 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
CRChristian Rausch
Christian Rausch
MRMaja Rothenberg-Thurley
Maja Rothenberg-Thurley
SBSimon A. Buerger
Simon A. Buerger
STSebastian Tschuri
Sebastian Tschuri
ADAnnika Dufour
Annika Dufour
FZFrank Ziemann
Frank Ziemann

4 November 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
AWAnna-Katharina Wirth
Anna-Katharina Wirth
LWLucas Wange
Lucas Wange
SVSebastian Vosberg
Sebastian Vosberg
KHKai-Oliver Henrich
Kai-Oliver Henrich
CRChristian Rausch
Christian Rausch
IJIrmela Jeremias
Irmela Jeremias
Resistance towards cancer treatment represents a major clinical obstacle, preventing cure of cancer patients. To gain mechanistic insights, we developed a model for acquired resistance to chemotherapy by treating mice carrying patient derived xenografts (PDX) of acute lymphoblastic leukemia with widely-used cytotoxic drugs for 18 consecutive weeks. In two distinct PDX samples, tumors initially responded to treatment, until stable disease and eventually tumor re-growth evolved under therapy, at highly similar kinetics between replicate mice. Notably, replicate tumors developed different mutations in TP53 and individual sets of chromosomal alterations, suggesting independent parallel clonal evolution rather than selection, driven by a combination of stochastic and deterministic processes. Transcriptome and proteome showed shared dysregulations between replicate tumors providing putative targets to overcome resistance. In vivo CRISPR/Cas9 dropout screens in PDX revealed broad dependency on BCL2, BRIP1 and COPS2. Accordingly, venetoclax re-sensitized derivative tumors towards chemotherapy, despite genomic heterogeneity, demonstrating direct translatability of the approach. Hence, despite the presence of multiple resistance-associated genomic alterations, effective rescue treatment for polychemotherapy-resistant tumors can be identified using functional testing in preclinical models.

27 October 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
MBMarius Bill
Marius Bill
JEJan-Niklas Eckardt
Jan-Niklas Eckardt
KDKonstanze Döhner
Konstanze Döhner
MRMaximillian-Alexander Röhnert
Maximillian-Alexander Röhnert
CRChristian Rausch
Christian Rausch
CRChristoph Röllig
Christoph Röllig
In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact of individual MR genes within the ELN, clinical, cytogenetic, and molecular data from 4,978 intensively treated AML patients were analyzed. Remission rates and survival outcomes were evaluated. For analyses in context of ELN2022 classification, patients carrying an MR mutation were excluded from the adverse group and analyzed separately; those with co-occurring favorable or intermediate features remained in their respective groups. Overall, 1698 patients (34.1%) harbored at least one MR mutation. Lower complete remission rates were observed in MR-mutated cases (65.7% vs 77.7%; p < 0.001) along with shorter event-free (HR 1.45; p < 0.001), relapse-free (HR 1.33; p < 0.001), and overall survival (HR 1.45; p < 0.001) were recorded. Gene-specific prognostic patterns emerged: ASXL1 , RUNX1 , SF3B1 , and U2AF1 mutations associated with adverse risk-like outcomes; SRSF2 and STAG2 aligned with intermediate-risk; BCOR , EZH2 , and ZRSR2 did not differ significantly from intermediate or adverse risk. These findings from a large cooperative cohort highlight prognostic heterogeneity among MR mutations and suggest that SRSF2 and STAG2 mutations are associated with less adverse risk patterns, comparable to intermediate-risk.

12 August 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
CRChristian Rausch
Christian Rausch
CSCharlotte Schwicht
Charlotte Schwicht
DDDaphne Doedens
Daphne Doedens
RFRoswitha Forstpointner
Roswitha Forstpointner
CWChristoph Benedikt Westphalen
Christoph Benedikt Westphalen
VHVolker Heinemann
Volker Heinemann